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Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by a
PML-RARA fusion due to a translocation t(15;17). Its sensitivity to treatment with all-trans retinoic acid (ATRA), which
causes differentiation of the abnormal promyelocytes, combined with anthracycline based chemotherapy makes it
the best curable subtype of acute myeloid leukemia. A rapid and accurate diagnosis is needed in the first place to
prevent (more) bleeding problems. Here we present a patient with a leukemia with an APL-like morphology but no
detectable PML-RARA fusion, as demonstrated by RT-PCR and cytogenetic analysis.
Results: Unexpectedly, karyotyping revealed numerous double minutes (dmins). Fluorescence in situ hybridization
(FISH) with DNA probes specific for the MYC-region showed the presence of multiple MYC amplicons. SNP-array
analysis uncovered amplification of the 8q24.13-q24.21 region, including the MYC-gene, flanked by deletions in
8q24.13 and 8q24.21-q24.22, and a homozygous deletion in 9p21.3, flanked by heterozygous deletions in the same
chromosome region.
Conclusions: The diagnosis was revised to AML, not otherwise specified (AML, NOS) and therefore therapy with
ATRA was discontinued.
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Acute promyelocytic leukemia (APL) is a hematological
emergency frequently associated with severe coagulation
disturbances. The typical morphology shows abnormal,
usually bilobed hypergranular promyelocytes. In some
cases the cytoplasmic granules are so large or numerous
that they completely fill the cell, obscuring the nuclear
cytoplasmic limit. Frequently characteristic cells contain-
ing bundles of Auer rods, the so-called faggot cells, are
seen. In APL, Sudan Black (SB) or myeloperoxidase
(MPO) is always strongly positive in all blast cells, with
the reaction product covering the whole cytoplasm and
often the nucleus too [1].
Cytogenetically a reciprocal translocation t(15;17)(q24;
q21) is present, leading to a fusion gene consisting of
the proximal part of the promyelocytic leukemia gene
(PML) on 15q24 and the distal part of the retinoic acid* Correspondence: p.poddighe@vumc.nl
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unless otherwise stated.receptor alpha (RARA) gene usually on 17q21 [2]. This
has therapeutic impact, since APL with a t(15;17) has a
particular sensitivity to treatment with all-trans retinoic
acid (ATRA). Treatment with ATRA, combined with
cytotoxic chemotherapy or arsenic trioxide (ATO) re-
sults in complete remission rates of over 90% [3]. The
high morbidity and mortality associated with the coagu-
lation abnormality already present in most patients at
diagnosis requires that ATRA must be initiated immedi-
ately after the diagnosis is suspected.
Rare cases of APL with typical morphology lack the
classic translocation in routine cytogenetic studies. They
may still express the PML-RARA transcript due to a
cryptic PML-RARA fusion gene e.g. as a result of an in-
sertion of the RARA gene near the PML gene on 15q24.
These APL have the same response to ATRA as the clas-
sical or hypergranular APL.
Another subgroup of APL, the so-called variant or
hypogranular APL, has the typical translocation t(15;17)
and is also ATRA responsive, but usually presents with
a leukocytosis, which may increase quickly. In theseral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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myelocytes but bilobed blasts with seemingly absent
granules and infrequent faggot cells and a strong posi-
tive SB or MPO reaction [4].
In the present study we present a case that morpho-
logically resembled a classic APL and was treated as such.
The diagnosis had to be reconsidered when additional in-
vestigations showed an unexpected cytogenetic result.
Case presentation
A 76-year-old man presented with exertional dyspnea,
visual disturbances, night sweats and progressive fatigue.
His medical history showed chronic obstructive pulmon-
ary disease, Diabetes Mellitus type 2, hypercholesterol-
emia and alcohol abuse. On physical examination he had
some petechiae and hematoma on the lower extremities.
No lymphadenopathy or organomegaly was found. His
white blood cell count was extremely elevated (220 ×
109/l). Hemoglobin was 6.5 mmol/l and platelets were
20 × 109/l. The peripheral blood smear revealed 37 ×
109/l blasts, with Auer rods, but also 78 × 109/l promye-
locytes, with some faggot cells, resembling typical APL
(Figure 1A). Other abnormal laboratory findings in-
cluded a LDH of 5230 U/l and creatinine of 130 micro-
mol/l. No coagulation abnormalities were present.
Since he had signs of leukostasis (dyspnea, visual dis-
turbances and tinnitus) he was immediately treated with
leukapheresis in addition to the administration of dauno-
rubicin (45 mg/m2) and, because of the typical APL
morphology, ATRA (45 mg/m2 in two doses per day).
Methods
Immunophenotyping
Flow cytometric analysis of the peripheral blood was
performed according to standard guidelines for immu-
nophenotyping of acute leukemia with some modifica-
tions (www.cytometrie.nl). An eight-color antibody panel
was applied; data were acquired on a FACSanto II flow
cytometer and analyzed with FACS-DIVA software (BD
Biosciences, San José, CA, USA).
Cytogenetic studies
The patient’s peripheral blood was set up in two 24-hour
RPMI 1640 cultures, one unstimulated and one stimu-
lated with growth factors G/CSF, IL3 and GM/CSF.
After standard cytogenetic harvesting and GTG banding
20 metaphase cells were analyzed from the stimulated
culture. The karyotype was described according to ISCN
2013 [5].
Fluorescence in situ hybridization (FISH) using directly
labeled probes was performed according to the manu-
facturer's instructions in combination with our established
laboratory protocol. The following probes were used:
Vysis LSI PML/RARA Dual Color Dual Fusion Probe(Abbott Molecular IL, Hoofddorp, The Netherlands), ON
MYC/IGH t(8;14) Fusion Probe (Kreatech, Amsterdam,






[Chr8:133,852,795-134,111,178 Mb(hg19)] and RP11-
268C19 [Chr8:134,410,759-134,585,494 Mb(hg19)] from
BlueGnome Ltd, Cambridge, UK.
Molecular diagnostics
RNA was isolated from mononuclear blood cells, using
RNAeasy (Qiagen). cDNA synthesis of 1 µg RNA was
performed using M-MLV (Invitrogen) and random hex-
amer primers (Roche). PML-RARa fusion transcripts
were amplified using RT-PCR according to Miller et al.
[6]. PCR products were analyzed on agarose gel. FLT3-
ITD RT-PCR followed by GeneScan analysis was done
as described previously [7].
Genomic profiling and data analysis
Microarray-based genomic profiling was carried out with
250 ng DNA isolated from peripheral blood using the
CytoScan HD array platform (Affymetrix, Inc., Santa
Clara, CA, USA) and was performed according to the
manufacturer’s protocol. The data obtained by the
CytoScan HD array platform were analyzed using Nexus
copy number software (Biodiscovery Inc., Hawthorne,
CA, USA) and annotations of genome version GRCh37
(hg19).
Results
Immunophenotyping showed a cell population that was
CD34 negative and positive for CD117, HLA-DR, MPO
and CD15, with heterogeneous expression of CD33+
and weak expression of CD13, CLIP expression was ab-
sent, and a second cell population with more monocytic
characteristics: positive for CD11b, CD11c, and aber-
rantly CD56.
Karyotyping revealed an abnormal male karyotype, but
instead of a translocation t(15;17) the cells showed 7 to
50 dmins (see Figure 1B): 46,XY,7~50dmin[20]. Inter-
phase FISH with the LSI PML/RARA DC DF probe
showed no PML-RARA fusion in 200 cells (results not
shown). Molecular analysis revealed that both PML-
RARa fusion and FLT3 were negative. Since double mi-
nutes in AML have mostly been described as consisting
of MYC, we performed FISH with the DNA probe ON
MYC/IGH t(8;14) Fusion Probe. This probe indeed showed
that the dmins stained positive for MYC (Figure 1C). Fur-
thermore, the MYC-probe signal was only present on one










Figure 1 Cytomorphologic and cytogenetic results. (A) A representative cytomorphologic bone marrow field, showing blasts with Auer rods
(arrow) and azurophilic inclusions. (B) A representative metaphase cell demonstrating normal chromosomes 15 and 17, and more than 20 double
minutes (red arrowheads). (C) Metaphase FISH of this patient with the ON MYC(green)/IGH(red) t(8;14) Fusion Probe (Kreatech), showing MYC-positive
dmins (green), and both chromosomes 14 (arrow); in this cell it was not possible to indicate the normal chromosome 8 due to the high number of
dmins (D) Metaphase FISH with a BAC-probe RP1-80K22 (base pair position 128,667,455-128,814,588) for MYC gene (red) and a flanking BAC-probe
RP11-125A17 (base pair position 128,865,417-129,036,660; green), demonstrating multiple copies of dmins (red-green signals). Only one chromosome 8
(arrow) contains the MYC gene region.
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was therefore adjusted: 46,XY,7-50dmin[20].ish del(8)
(q24.2q24.2)(MYC-), dmin(MYCx7~50)[10].
Genome-wide SNP array analysis revealed an amplifi-
cation of 4,56 Mb on 8q24.13-q24.21, which contained
15 genes, including MYC, flanked by a proximal deletion
at 8q24.13 of 693 kb (10 genes) and a distal deletion at
8q24,21 of 1,07 Mb (6 genes) (see Figure 2A and Table 1).On 9p21.3 a deletion of 2,28 Mb (31 genes) was observed,
of which 442 kb was homozygous (see Figure 2B and
Table 1).
Additional FISH with the probe combination RP1-
80K22 (overlapping the MYC-gene) and a distal flanking
BAC-probe RP11-125A17 confirmed that the dmins
contained more than the MYC-gene (see Figure 1D).







A Chromosome 8 
B Chromosome 9 
Figure 2 SNP-array results for chromosome regions 8q24 (A) and 9p21.3 (B). (A) The log2 ratio demonstrate that amplification of the
MYC-region of 4.57 Mb (section 2) is flanked by a proximal deletion of 693 kb (section 1) and a distal deletion of 1,07 Mb (section 3). (B) The
homozygous deletion of 483 kb (section 5) is flanked by a distal heterozygous deletion of 1.39 Mb (section 4) and a proximal deletion of 423 kb
(section 6). BAF = biallelic frequency.
Table 1 Overview of genomic aberrations detected by SNP-array
Chromosome
region
Genomic position Length (base pairs) Copy number Gene symbol
8q24.13q24.13 125,444,383-126,137,622 693.240 Deletion TRMT12, RNF139, TATDN1, NDUFB9, MTSS1, LOC157381,
ZNF572, SQLE, KIAA0196, NSMCE2
8q24.13q24.21 126,137,622-130,706,799 4.569.178 Amplification NSMCE2, TRIB1, LOC100130231, FAM84B, PCAT1, POU5F1B,
LOC727677, MYC, MIR1204, MIR1205, PVT1, MIR1206,
MIR1207, MIR1208, LOC728724
8q24.21q24.22 130,706,799-131,782,618 1.075.820 Deletion GSDMC, FAM49B, MIR5194, LOC100507117, ASAP1, ASAP1-IT1
9p21.3p21.3 20,571,017-21,966,002 1.394.986 Deletion MLLT3, MIR491, FOCAD, PTPLAD2, IFNB1, IFNW1, IFNA21,
IFNA4, IFNA7, IFNA10, IFNA16, IFNA17, IFNA14, IFNA22P,
IFNA5, KLHL9, IFNA6, IFNA13, IFNA2, IFNA8, IFNA1, IFNE,
MIR31HG, MIR31, MTAP
9p21.3p21.3 21,966,002-22,408,814 442.813 Homozygous deletion C9orf53, CDKN2A, CDKN2B, CDKN2B-AS1
9p21.3p21.3 22,408,814-22,851,531 442.718 Deletion DMRTA1, FLJ35282
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the dmins, whereas the distal flanking DNA probes
RP11-316E19 and RP11-268C19 were absent (results
not shown).







Following leukapheresis and administration of dauno-
rubicin leucocyte counts dropped to 0.9 109/l. Based on
the additional investigations the diagnosis of APL was al-
tered to AML, not otherwise specified (AML, NOS) [4].
The patient’s age and physical condition didn’t allow
to deliver intensive anti-leukemic chemotherapy. He
subsequently developed a paralytic ileus and hypotension
and died.
Conclusions
In this report we describe a patient with a rare APL-like
phenotype. At presentation the peripheral blood smears
showed a typical APL morphology. However, immuno-
phenotyping results were not typical for APL, that is
usually HLADR negative with homogeneous expression
of CD33 and CLIP positive [8]. Moreover, the extreme
leukocytosis and also the absence of abnormal coagula-
tion tests did not fit in with the diagnosis of APL. In
hypogranular APL the leucocyte count can be very high
with a rapid doubling time, but the patient’s cell morph-
ology and immunophenotyping didn’t resemble a hypo-
granular APL. The additional investigations confirmed
this; there was no detectable PML-RARA fusion product
present. In fact, cytogenetic analyses showed no t(15;17),
but the presence of 7 to 50 double minutes (dmins).
SNP-array identified a 4,56 Mb large amplicon (contain-
ing 15 genes), flanked by a proximal deletion of 693 kb
(10 genes) and a distal deletion of approximately 1,07
Mb (6 genes), as well as a homozygous deletion in
9p21.3 of 443 kb (4 genes), which was flanked by two
heterozygous deletions: one distal deletion of about 1,4
Mb (25 genes) and one proximal deletion of 443 kb (2
genes), see Table 1.
Amplification of human chromosome region 8q24 has
been associated with many types of solid tumors, such
as breast, prostate, colon, lung, ovaries and pancreas
[9-11]. The genes in this region are mostly all oncogenes
or tumor suppressor genes, affecting general cancer sus-
ceptibility. In general, the MYC-gene is involved in this
amplification and can be present as dmins or homoge-
neously staining regions (hsr). Gene amplification in
AML is rare, the most frequent gene involved being
MYC and the second most common oncogene MLL[12], mostly as part of a complex karyotype. MYC amp-
lification manifesting as dmins has been described in
only a few cases with an APL or APL-like morphology
[13-15].
In solid tumors, such as colon, pancreatic and breast
carcinomas, brain tumors and neuroblastomas, dmins
can be observed as a late genomic event in tumorigen-
esis, the dmins being associated with a rapid cellular
growth and poor prognosis. In AML dmins appear less
frequently, in about 1% of the cases [12,16,17]. The me-
chanism of the excision of DNA segments from an
otherwise intact chromosome, followed by circulariza-
tion and amplification by mutual recombination to pro-
duce dmins, has been described by Carroll et al. [18].
Storlazzi et al. [19] have provided evidence for this
so-called episomal model for the formation of MYC-
containing dmin in acute myeloid leukemia.
The deletion in 8q was larger than the amplified seg-
ment in dmins, and this phenomenon was also observed
in a study by Storlazzi et al. [20], who describe a
chromosomal deletion in 8q24 corresponding to or lar-
ger than the amplicon in 68% of 34 investigated AML/
MDS cases, suggesting post-replicative excision of DNA
followed by circularization (episome) as the mechanism
behind the dmin formation.
The first patient with MYC amplification in dmins as
the sole cytogenetic aberration has been described by
Frater et al. [15]. Also in our patient the excision of
MYC from 8q24 with subsequent amplification of this
region into dmins may have led to upregulation of the
expression of the MYC oncogene, a known critical nu-
clear transcription factor.
Deletions of 9p are not frequent recurrent chromo-
some aberrations in AML. Usvasalo et al. [21] repor-
ted a study in which multiple areas of copy number
loss, or homozygous loss within a larger heterozygous
loss region, in 9p was restricted to ALL patients, and
was not observed in AML patients. Interestingly, the
APL-like patient without a PML-RARA fusion pre-
sented by Bruyère et al. [13] showed MYC amplification
as dmins and an apparently terminal deletion of the
short arm of chromosome 9 with the breakpoint at
band p21. Our findings support their suggestion that
there might be an association between loss of 9p,
dmins, and an APL-like morphology.
In summary, we describe a patient with an APL-like
morphology, who showed no PML-RARA fusion but
MYC amplification in dmins. It is of utmost importance
to have a rapid confirmation or exclusion of t(15;17) in
an acute leukemia that morphologically resembles APL.
Therefore, in our routine practice we have implemented
a rapid, four hours interphase FISH test using a LSI
PML/RARA DC DF Probe (Vysis) on bone marrow
or blood smears from patients suspected for APL. In
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patient died soon after diagnosis from abdominal sep-
sis before proper treatment could be initiated.
Consent
Informed consent was obtained from the patient for
the publication of this report and any accompanying
images.
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